Other Events ·
Cellyan Biotechnology received a notification from Nasdaq on July 14, 2026, granting an additional 180-day grace…
HKPDCellyan Biotechnology Co., Ltd
Cellyan Biotechnology received a notification from Nasdaq on July 14, 2026, granting an additional 180-day grace period to regain compliance with the minimum $1.00 closing bid price requirement. The company must maintain a closing bid price of at least $1.00 per Class A ordinary share for ten consecutive business days on or before January 11, 2027. This extension follows a previous deficiency notice issued on January 12, 2026. The company may consider a reverse share split to restore compliance. Cellyan Biotechnology provides over the counter pharmaceutical cross-border e-commerce supply chain services.